BR112014016624A8 - forma de dosagem sólida compreendendo nicotina com perturbação organoléptica reduzida - Google Patents

forma de dosagem sólida compreendendo nicotina com perturbação organoléptica reduzida

Info

Publication number
BR112014016624A8
BR112014016624A8 BR112014016624A BR112014016624A BR112014016624A8 BR 112014016624 A8 BR112014016624 A8 BR 112014016624A8 BR 112014016624 A BR112014016624 A BR 112014016624A BR 112014016624 A BR112014016624 A BR 112014016624A BR 112014016624 A8 BR112014016624 A8 BR 112014016624A8
Authority
BR
Brazil
Prior art keywords
nicotine
dosage form
disturbance
solid dosage
film coating
Prior art date
Application number
BR112014016624A
Other languages
English (en)
Other versions
BR112014016624A2 (pt
Inventor
Hugerth Andreas
Nicklasson Fredrik
Lindell Katarina
Thyresson Kristina
Original Assignee
Mcneil Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ab filed Critical Mcneil Ab
Publication of BR112014016624A2 publication Critical patent/BR112014016624A2/pt
Publication of BR112014016624A8 publication Critical patent/BR112014016624A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "forma de dosagem sólida compreendendo nicotina com perturbação organoléptica reduzida". a presente invenção refere-se a forma de dosagem farmacêutica sólida para a liberação de nicotina dentro da cavidade oral compreendendo um núcleo encapsulado por, pelo menos, um revestimento de filme, em que o núcleo compreende nicotina e em que o revestimento de filme compreende pelo menos um polímero formador de filme e pelo menos um componente para redução de uma ou mais sensações organolepticamente perturbadoras, e em que o pelo menos um revestimento de filme está desprovido de nicotina e desprovido de tampão.
BR112014016624A 2012-01-05 2013-01-07 forma de dosagem sólida compreendendo nicotina com perturbação organoléptica reduzida BR112014016624A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1200017 2012-01-05
PCT/SE2013/050005 WO2013103318A1 (en) 2012-01-05 2013-01-07 Solid nicotine-comprising dosage form with reduced organoleptic disturbance

Publications (2)

Publication Number Publication Date
BR112014016624A2 BR112014016624A2 (pt) 2017-06-13
BR112014016624A8 true BR112014016624A8 (pt) 2017-07-04

Family

ID=48744083

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016624A BR112014016624A8 (pt) 2012-01-05 2013-01-07 forma de dosagem sólida compreendendo nicotina com perturbação organoléptica reduzida

Country Status (19)

Country Link
US (1) US20130177646A1 (pt)
EP (1) EP2800557B1 (pt)
JP (1) JP6169609B2 (pt)
KR (1) KR102056041B1 (pt)
CN (1) CN104053433A (pt)
AR (1) AR089670A1 (pt)
AU (1) AU2013206983B2 (pt)
BR (1) BR112014016624A8 (pt)
CA (1) CA2862497C (pt)
DK (1) DK2800557T3 (pt)
ES (1) ES2848534T3 (pt)
HK (1) HK1201448A1 (pt)
HU (1) HUE053063T2 (pt)
MX (1) MX370218B (pt)
NZ (1) NZ626672A (pt)
PH (1) PH12014501446B1 (pt)
PL (1) PL2800557T3 (pt)
WO (1) WO2013103318A1 (pt)
ZA (1) ZA201405745B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014157264A1 (ja) * 2013-03-27 2014-10-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 口腔内崩壊性フィルムコーティング錠
PL3003285T3 (pl) * 2013-06-03 2022-06-20 Mcneil Ab Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej
WO2015068058A1 (en) * 2013-11-06 2015-05-14 Rk Technology & Investments Pte. Ltd. Tobacco free 'niconuts'and the process thereof
JP6672258B2 (ja) * 2014-04-08 2020-03-25 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン製剤及びその作製方法
CN104489916B (zh) * 2014-12-02 2016-06-01 云南中烟工业有限责任公司 红醋栗提取物在卷烟中的应用
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US9585835B1 (en) 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
MX2019000219A (es) 2016-07-05 2019-09-04 Glaxosmithkline Consumer Healthcare Holdings Us Llc Forma de dosificación oral que contiene un revestimiento exterior de liberación rápida.
CN110650732A (zh) 2017-05-22 2020-01-03 强生消费者公司 锭剂剂型
CA3085063C (en) * 2017-12-08 2024-05-21 Fertin Pharma A/S Solid oral nicotine formulation
AU2018378648B2 (en) * 2017-12-08 2021-06-03 Fertin Pharma A/S Nicotine tablet
CA3085065C (en) 2017-12-08 2023-12-05 Fertin Pharma A/S Formulations providing high nicotine concentrations
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
CA3160750A1 (en) 2019-12-09 2021-06-17 Anthony Richard Gerardi Oral product comprising a cannabinoid
US11672862B2 (en) 2019-12-09 2023-06-13 Nicoventures Trading Limited Oral products with reduced irritation
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US11883527B2 (en) 2019-12-09 2024-01-30 Nicoventures Trading Limited Oral composition and method of manufacture
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
US11889856B2 (en) 2019-12-09 2024-02-06 Nicoventures Trading Limited Oral foam composition
SE544672C2 (en) * 2020-05-07 2022-10-11 Liw Innovation Ab New compositions for oral or nasal use
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
US20220387328A1 (en) * 2021-06-04 2022-12-08 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Dosage form for nicotine replacement therapy
US20230109240A1 (en) * 2021-09-30 2023-04-06 L'oreal Compositions and methods for styling hair
CN117256920A (zh) * 2023-09-27 2023-12-22 东莞市吉纯生物技术有限公司 一种固体雾化物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1219291A (en) * 1910-12-13 1917-03-13 Chester Earl Gray Process of manufacturing products from milk and cream.
GB2230439A (en) * 1989-04-20 1990-10-24 Alec Stanley Walter Shaw Nicotine lozenges
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
JP3707798B2 (ja) * 1996-05-13 2005-10-19 ノバルティス・コンシューマー・ヘルス・ソシエテ・アノニム 口内薬剤輸送系
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6583160B2 (en) * 1999-04-14 2003-06-24 Steve Smith Nicotine therapy method and oral carrier for assuaging tobacco-addiction
JP4044709B2 (ja) * 1999-11-19 2008-02-06 信越化学工業株式会社 水系フィルムコーティング剤及び経口固形製剤
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
US20020119196A1 (en) * 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
SE0102197D0 (sv) * 2001-06-20 2001-06-20 Pharmacia Ab New product and use and manufacture thereof
WO2003003957A1 (en) * 2001-07-06 2003-01-16 Lavipharm Laboratories Inc. Quick dissolving oral mucosal drug delivery device with moisture barrier coating
JP5089840B2 (ja) * 2001-09-25 2012-12-05 救急薬品工業株式会社 ニコチン含有フィルム製剤
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
SG108299A1 (en) * 2002-06-11 2005-01-28 Inst Data Storage Method and apparatus for forming periodic structures
JP4708795B2 (ja) * 2002-12-20 2011-06-22 ニコノヴァム エービー 物理的および化学的に安定なニコチン−含有粒状物質
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
US7022750B2 (en) * 2003-04-04 2006-04-04 Ppg Industries Ohio, Inc. Anti-fouling coating containing copper and graphite
GB0320854D0 (en) * 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
US20070269492A1 (en) * 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
US20080286341A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
PT2293786E (pt) * 2008-05-21 2015-02-25 Novartis Ag Gomas de mascar que podem ser transformadas em comprimidos compreendendo nicotina e um agente tampão
DK2296486T3 (en) * 2008-05-26 2015-07-13 Fertin Pharma As Film-coated compressed gum
WO2010044736A1 (en) * 2008-10-14 2010-04-22 Mcneil Ab Multi portion intra-oral dosage form and use thereof
EP2233134A1 (en) * 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
US20110268809A1 (en) * 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions

Also Published As

Publication number Publication date
HK1201448A1 (en) 2015-09-04
ES2848534T3 (es) 2021-08-10
HUE053063T2 (hu) 2021-06-28
RU2014132174A (ru) 2016-02-27
EP2800557A4 (en) 2015-09-09
KR20140108728A (ko) 2014-09-12
CA2862497C (en) 2020-04-14
CA2862497A1 (en) 2013-07-11
KR102056041B1 (ko) 2019-12-16
RU2623018C2 (ru) 2017-06-21
DK2800557T3 (da) 2021-02-15
MX2014008271A (es) 2014-10-06
JP2015503581A (ja) 2015-02-02
PL2800557T3 (pl) 2021-06-14
BR112014016624A2 (pt) 2017-06-13
US20130177646A1 (en) 2013-07-11
WO2013103318A1 (en) 2013-07-11
MX370218B (es) 2019-12-05
PH12014501446A1 (en) 2014-10-08
NZ626672A (en) 2016-11-25
EP2800557B1 (en) 2020-12-30
CN104053433A (zh) 2014-09-17
AU2013206983B2 (en) 2017-10-05
AU2013206983A1 (en) 2014-07-03
PH12014501446B1 (en) 2014-10-08
ZA201405745B (en) 2016-06-29
AR089670A1 (es) 2014-09-10
EP2800557A1 (en) 2014-11-12
JP6169609B2 (ja) 2017-07-26

Similar Documents

Publication Publication Date Title
BR112014016624A8 (pt) forma de dosagem sólida compreendendo nicotina com perturbação organoléptica reduzida
BR112015030140A2 (pt) forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral
BR112015002421A2 (pt) composição farmacêutica ou nutracêutica com características de liberação sustentada e com resistência contra a influência do etanol
BR112015026549A2 (pt) forma de dosagem à prova de violação contendo uma ou mais partículas
BR112015001371A2 (pt) composição farmacêutica ou nutracêutica resistente ao suco gástrico com resistência contra a influência de etanol
BR112013004416A2 (pt) agente terapêutico para enfisema pulmonar
BR112012002817B8 (pt) composições sublinguais e bucais em filme
BR112015017451A2 (pt) formulações farmacêuticas resistentes à violação
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
BR112015021619A8 (pt) filtro para artigo fumígeno e artigo fumígeno
BR112014005563A2 (pt) método para fornecer dados em um sistema de computação
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
BR112013031406A2 (pt) forma de dosagem oral comestível em tira ou disco contendo resina de troca iônica para mascarar o sabor
BR112019001852A2 (pt) composição de cannabis
BR112015021002A2 (pt) forma de dosagem sólida restringente de abuso para liberação imediata com entalhe funcional
BRPI0922796A2 (pt) Comprimido farmacêutico para administração por via oral e método de fabricação do mesmo
MX352192B (es) Formas de dosificación sólidas que comprenden miel en el recubrimiento.
BR112012026596A2 (pt) método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
BR112012020989A2 (pt) composições veterinárias
BR112013030727A2 (pt) dispositivos para inalação de insumos medicinais, válvulas e componentes do mesmo
BR112013032095A2 (pt) composição de revestimento adequada para formas de dosagem farmacêuticas ou nutracêuticas
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
CY1113671T1 (el) Θεραπεια γνωστικων διαταραχων με (r)-7-χλωρο-ν-(κινουκλιδιν-3-υλ)βενζο[b]θειοφαινο-2-καρβοξαμιδιο και τα φαρμακευτικως αποδεκτα αλατα του

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]